Every material Form 8-K CURIS INC has filed with the SEC since May 12, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Curis received a Nasdaq letter on November 2, 2026 stating its stock closed below the $1.00 minimum bid price for 30 consecutive business days, and it is not eligible for a standard compliance period because of its recent reverse stock split. The company intends to request a new hearing, which would stay further delisting actions, but says there is no assurance the appeal will succeed or that its shares will remain listed on Nasdaq.
Nasdaq letter dated November 2, 2026 cites bid price below $1.00 for 30 consecutive business days under Rule 5550(a)(2)
Company effected a 1-for-20 reverse stock split on July 6, 2026, which makes it ineligible for a compliance period
Following a Nasdaq Hearings Panel decision dated July 24, 2026, Curis is subject to a Discretionary Panel Monitor for one year
Company intends to request a new hearing; no assurance of success or continued Nasdaq listing
On October 16, 2026, Curis agreed to sell 16,666,680 shares, or pre-funded warrants in place of shares, with accompanying common warrants for up to 16,666,680 shares, at a combined price of $0.51 per share. Gross proceeds are expected to be about $8.5 million before placement agent fees and expenses, with closing expected on or about October 19, 2026. The company also agreed to lower the exercise price of its January and August 2026 warrants to $0.60, and the new share count and warrants would add to the shares outstanding for existing holders.
Offering of 16,666,680 shares or pre-funded warrants, plus common warrants for up to 16,666,680 shares, at a combined $0.51 per share
Gross proceeds expected to be about $8.5 million, before placement agent fees and offering expenses; placement agents to receive a 6.5% cash fee
New common warrants have a $0.60 exercise price, become exercisable six months after issuance, and terminate April 19, 2032
January 2026 and August 2026 warrants to be amended to a reduced exercise price of $0.60; proceeds expected to fund operations through initial CLL data in 5-10 patients in December 2026
Curis received written notice from Nasdaq on July 24, 2026 that it has regained compliance with the bid price rule and is in full compliance with the Nasdaq Hearings Panel's terms. The company will be subject to a one-year Discretionary Panel Monitor from July 24, 2026, meaning any new continued listing deficiency would lead to a delist determination and a hearing without additional time to cure, and there is no assurance it will remain listed.
Nasdaq notice dated July 24, 2026 confirms regained compliance with Listing Rule 5550(a)(2), the bid price rule
Discretionary Panel Monitor applies for one year from July 24, 2026 under Listing Rule 5815(d)(4)(A)
Any new continued listing deficiency during the monitor period gets no plan of compliance or extra time to cure
Filing states there can be no assurance Curis will remain listed on Nasdaq
Curis reported a first-quarter 2026 net loss of $24.2 million, or $1.25 per share, compared with $10.6 million, or $1.25 per share, a year earlier. Revenue fell to zero after the company sold its Erivedge royalties to Oberland in the fourth quarter of 2025, and a change in the fair value of a warrant liability drove most of the larger loss. The company says its planned operations into the second half of 2027 depend on warrant exercises tied to a clinical milestone.
Q1 2026 revenue was zero, compared with $2.4 million in Q1 2025, after the Erivedge royalty sale to Oberland.
Other expense was $12.7 million, mainly from the change in fair value of the warrant liability tied to the January 2026 PIPE Financing, versus $0.5 million a year earlier.
Cash and cash equivalents were $15.0 million at March 31, 2026; the filing states the company does not have sufficient cash to support operations for the next 12 months.
Up to $20.2 million from Series B warrant exercises depends on announcing dosing of the fifth CLL patient, which is expected later this year.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every CURIS INC filing is on SEC EDGAR ↗. 8-K briefs of other companies →